A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety
run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in
Patients with Metastatic Colorectal Cancer (mCRC).